Skip to main content

Table 2 Age, gender, comorbidities and RASB intake relationship with COVID-19 severity

From: COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study

 

Mild

Moderate

Severe

Age (p = 0.019)

n (%)

n (%)

n (%)

 < 30

10 (43.5)

9 (39.1)

4 (17.4)

 30–45

26 (37.7)

26 (37.7)

17 (24.6)

 45–60

41 (26.6)

62 (40.3)

51 (33.1)

 60–75

57 (30.6)

80 (43.0)

49 (26.3)

 > 75

26 (17.1)

69 (45.4)

57 (37.5)

Gender (p < 0.001)

 Male

77 (22.1)

144 (41.3)

128 (36.7)

 Female

83 (35.3)

102 (43.4)

50 (21.3)

Hypertension (p = 0.015)

 No

91 (33.7)

107 (39.6)

72 (26.7)

 Yes

67 (22.9)

132 (45.1)

94 (32.1)

Dyslipidemia (p = 0.006)

 No

127 (32.2)

159 (40.4)

108 (27.4)

 Yes

30 (18.9)

75 (47.2)

54 (34.0)

Diabetes (p = 0.003)

 No

134 (31.8)

175 (41.5)

113 (26.8)

 Yes

23 (17.6)

59 (45.0)

49 (37.4)

Immunodeficiency

 No

283 (60.6)

379 (81.0)

273 (58.4)

 Yes

8 (68.4)

21 (102.6)

11 (28.9)

RASBa intake

 No

10 (17.9)

32 (57.1)

14 (25.0)

 Yes

50 (23.9)

91 (43.5)

68 (34.0)

 

Mild-Moderate

Severe

 

RASBa intake

n (%)

n (%)

 

 No

42 (75)

14 (25)

 

 Yes

142 (67.9)

67 (32.1)

 

ACEb intake (p = 0.046)

 No

111 (65.3)

59 (34.7)

 

 Yes

71 (77.2)

21 (22.8)

 

ARBc intake (p = 0.004)

 No

95 (77.9)

27 (22.1)

 

 Yes

76 (60.8)

49 (39.2)

 
  1. Abbreviations: p Chi Squared p-values, RASBa Renin-angiotensin system blockers, ACEb Angiotensin-converting enzyme inhibitors, ARBc Angiotensin II receptor blockers